Abstracts tagged "immune-related adverse events"

Abstract Number: 1521 • ACR Convergence 2021
Autoantibody Microarray Signal Intensities May Predict the Occurrence of Immune-related Adverse Events
Nilasha Ghosh¹, Chengsong Zhu², Karmela Kim Chan³, Michael Postow⁴ and Anne Bass⁵, ¹Hospital for Special Surgery, New York, NY, ²UT Southwestern, Dallas, TX, ³Hospital for Special Surgery, New York, NY, ⁴Memorial Sloane Kettering Cancer Center, New York, NY, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICI) are a novel cancer therapeutic that have had a dramatic impact on treating advanced malignancies by enhancing the anti-tumor T…
Abstract Number: 1516 • ACR Convergence 2021
Clinical Phenotypes and Treatment of Rheumatic Immune-Related Adverse Events from Checkpoint Inhibitors: A Retrospective Cohort of 112 Patients
Tiphaine Lenfant¹, Yuxuan Jin², Elizabeth Kirchner³, Pauline Funchain², Jung-Min Song², Moshe Ornstein², Laura Wood², Donald Eicher², Rula Hajj-Ali⁴, Leonard Calabrese² and Cassandra Calabrese⁵, ¹Institut Mutualiste Montsouris, Paris, France, ²Cleveland Clinic, Cleveland, OH, ³CCF, Cleveland, OH, ⁴Cleveland Clinic, Hunting Valley, OH, ⁵Cleveland Clinic Foundation, Cleveland Heights, OH
Background/Purpose: To describe a single center cohort of rheumatic immune related adverse events (irAEs) observed in patients treated with checkpoint inhibitor therapy (ICI) and to…
Abstract Number: 1519 • ACR Convergence 2021
Concomitant Targeted Therapy with Ongoing Immune Checkpoint Inhibitor (ICI) Therapy for Severe Immune Related Adverse Events (irAEs): Clinical Experience from Two Centers
Cassandra Calabrese¹, Khashayar Esfahani² and Leonard Calabrese³, ¹Cleveland Clinic Foundation, Cleveland Heights, OH, ²Jewish General Hospital, Department of Oncology, McGill University, Montréal, QC, Canada, ³Cleveland Clinic, Cleveland, OH
Background/Purpose: Treatment of irAEs is a balance of suppressing irAE-associated hyper-inflammation without inhibiting anti-tumoral effects of ICI. Treatment of grade 3/4 irAEs is most challenging…
Abstract Number: 1520 • ACR Convergence 2021
Do Specific Rheumatic Autoantibodies Predict Severity or Time to Onset of Immune-related Adverse Events from Checkpoint Inhibitors?
Nilasha Ghosh¹, Deanna Jannat-Khah², Karmela Kim Chan², Michael Postow³ and Anne Bass⁴, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Memorial Sloane Kettering Cancer Center, New York, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICI) are a novel cancer therapeutic that have had a dramatic impact on treating advanced malignancies by enhancing the anti-tumor T…
Abstract Number: 2138 • 2019 ACR/ARP Annual Meeting
Rheumatic Immune-related Adverse Effects from Checkpoint Inhibitor Immunotherapy in Patients with Solid Tumors in a Latin American Population
Alain Sánchez-Rodríguez¹, Elina Alexandra Rodriguez-Melendez ², Alonso Turrent-Carriles ³, Paola Bermúdez-Bermejo ³, josé Fabián Martínez-Herrera ² and Raquel Gerson-Cwilich ², ¹Hospital General de Mexico, Mexico City, Distrito Federal, Mexico, ²ABC Medical Center, Oncology Department, Ciudad de Mexico, Distrito Federal, Mexico, ³ABC Medical Center, Rheumatology Department, Ciudad de Mexico, Distrito Federal, Mexico
Background/Purpose: Cancer immunotherapy is a newly-approved approach in the management of advanced malignancies. Immune checkpoint inhibitors (ICIs) are the most commonly used type of cancer…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].